CYTX - Cytori Therapeutics, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.9505
-0.0245 (-2.51%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close0.9750
Open0.9300
Bid0.9400 x 1600
Ask1.2700 x 1000
Day's Range0.9200 - 0.9660
52 Week Range0.9100 - 8.7000
Volume213,130
Avg. Volume275,711
Market Cap5.849M
Beta1.76
PE Ratio (TTM)N/A
EPS (TTM)-5.6350
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.75
Trade prices are not sourced from all markets
  • GlobeNewswire6 days ago

    Cytori Reminds Stockholders That Rights Offering Expires on Friday, July 20

    Cytori Therapeutics, Inc. (CYTX) provides a reminder to stockholders that its previously announced rights offering will remain open until 5:00 PM Eastern Time on Friday, July 20, 2018. Rights holders will need to exercise their subscription rights prior to that date and time. The unit pricing remains $1,000 per unit, each unit consisting of one share of Series C Preferred Stock with a face value of $1,000 (and immediately convertible into common stock at a conversion price of the lesser of (a) $1.45 per share and (b) 85% of the lowest daily volume weighted average price for our common stock, as reported at the close of trading by Nasdaq, during the five trading days prior to the expiration of the rights offering (including the expiration date), subject to adjustment) and 621 warrants.

  • GlobeNewswire13 days ago

    Cytori Reports Sustained Benefit of Cell Therapy in Erectile Dysfunction Trial

    SAN DIEGO, July 09, 2018-- Cytori Therapeutics, Inc. announced publication in the peer-reviewed journal, Urology, of“ A 12- Month Follow-up After a Single Intracavernous Injection of Autologous Adipose-derived ...

  • GlobeNewswire24 days ago

    Cytori Reports Improved Skin Healing in Pivotal Burn Preclinical Study

    Cytori Therapeutics, Inc. (CYTX) announced today the publication of preclinical data from a study using intravenous delivery of Cytori Cell Therapy™ in a model of large burn injury representative of patients being recruited in the ongoing RELIEF clinical trial. This study was performed with support from the Biomedical Advanced Research and Development Authority (BARDA) as a component of the preclinical data supporting the FDA approved United States RELIEF Trial. In the study described in this publication, Adipose Derived Regenerative Cells (ADRCs), the active component of Cytori Cell Therapy™, were delivered by intravenous injection in a porcine model of mixed full-and partial thickness burn injury covering approximately 20% of total body surface area in which full thickness burns were treated with a meshed autologous split-thickness skin graft.

  • Benzinga25 days ago

    Benzinga's Daily Biotech Pulse: Pain Therapeutics Drops 70%, Neon To Begin Trading

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on June 26) AngioDynamics, Inc. (NASDAQ: ANGO ) Chembio Diagnostics Inc ...

  • GlobeNewswirelast month

    Cytori Therapeutics Reminds Investors of Today’s Deadline to be a Shareholder of Record

    Cytori Therapeutics, Inc. (CYTX) (“Cytori” or the “Company”) today issued a reminder to shareholders that the Record Date of its proposed rights offering is June 26, 2018. To be a shareholder of record, ownership of Cytori stock must occur by market close of June 22, 2018 to account for settlement. Under the proposed rights offering, Cytori will distribute one non-transferable subscription right for each share of common stock and Series B Convertible Preferred Stock (on an as-if-converted-to-common-stock basis) held on the record date.  Each right will entitle the holder to purchase one unit, at a subscription price of $1,000 per unit, consisting of one share of Series C Convertible Preferred Stock with a face value of $1,000 (and immediately convertible into shares of Cytori’s common stock at a conversion price of $2.64 per share) and 200 warrants to purchase Cytori’s common stock with an exercise price of $3.17 per share.  The warrants will be exercisable for 30 months after the date of issuance.

  • GlobeNewswirelast month

    Cytori Informs Stockholders of Key Dates and Terms Related to Announced Rights Offering

    Cytori Therapeutics, Inc. (CYTX) ("Cytori"), today provided an informational update to stockholders regarding its proposed rights offering and the expected key dates and terms relative to the offering. Stockholders are advised to ensure they complete their open market purchases of Cytori common stock by Friday, June 22, 2018 to be considered a stockholder of record on Tuesday, June 26, 2018.  Stockholders or interested parties are advised to direct all questions and informational requests to the contacts listed below. Under the proposed rights offering, Cytori will distribute one non-transferable subscription right for each share of common stock and Series B Convertible Preferred Stock (on an as-if-converted-to-common-stock basis) held on the record date.  Each right will entitle the holder to purchase one unit, at a subscription price of $1,000 per unit, consisting of one share of Series C Convertible Preferred Stock with a face value of $1,000 (and immediately convertible into shares of Cytori’s common stock at a conversion price of $2.64 per share) and 200 warrants to purchase Cytori’s common stock with an exercise price of $3.17 per share.  The warrants will be exercisable for 30 months after the date of issuance.

  • Cytori Therapeutics Inc (NASDAQ:CYTX): Are Analysts Optimistic?
    Simply Wall St.2 months ago

    Cytori Therapeutics Inc (NASDAQ:CYTX): Are Analysts Optimistic?

    Cytori Therapeutics Inc’s (NASDAQ:CYTX): Cytori Therapeutics, Inc., a therapeutics company, together with its subsidiaries, develops regenerative and oncologic therapies from its proprietary cell therapy and nanoparticle platforms for various medicalRead More...

  • Benzinga2 months ago

    Benzinga's Daily Biotech Pulse: Eiger And Melinta Fall On Offerings, Apellis And Marinus Rise On Bullish Ratings

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on May 23) ABIOMED, Inc. (NASDAQ: ABMD ) ArQule, Inc. (NASDAQ: ARQL ) Crispr ...

  • GlobeNewswire2 months ago

    Cytori Therapeutic’s common stock to begin trading on adjusted basis on May 24, following one-for-ten reverse split

    Cytori Therapeutics (CYTX) (“Cytori” or the “Company”) today announced that the Company effected a reverse stock split that became effective on May 23, 2018 at a ratio of one-for-ten, and that the Company’s common stock will commence trading on a post-split basis beginning on May 24, 2018. The Company received the requisite stockholder approval for the reverse stock split on May 18, 2018. The new CUSIP number for the Company’s common stock will be 23283K402.

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of CYTX earnings conference call or presentation 10-May-18 9:30pm GMT

    Q1 2018 Cytori Therapeutics Inc Earnings Call

  • Business Wire2 months ago

    SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Cytori Therapeutics, Inc.

    Levi & Korsinsky announces it has commenced an investigation of Cytori Therapeutics, Inc. concerning possible breaches of fiduciary duty. To obtain additional

  • Associated Press2 months ago

    Cytori: 1Q Earnings Snapshot

    On a per-share basis, the San Diego-based company said it had a loss of 7 cents. The developer of cell therapies posted revenue of $731,000 in the period. In the final minutes of trading on Thursday, the ...

  • GlobeNewswire2 months ago

    Cytori Reports Q1 2018 Business and Financial Results

    SAN DIEGO, May 10, 2018-- Cytori Therapeutics today announced Q1 2018 financial results and provided updates on corporate development.. Q1 2018 net loss was $4.4 million, or $0.07 per share. Operating ...

  • GlobeNewswire2 months ago

    Cytori to Webcast First Quarter Financial Results on May 10

    Cytori Therapeutics, Inc. (CYTX) will provide a live webcast of its first quarter financial results and business update on Thursday, May 10, 2018 at 5:30 PM Eastern Time. Cytori is a therapeutics company developing regenerative and oncologic therapies from its proprietary cell therapy and nanoparticle platforms for a variety of medical conditions. Cytori Nanomedicine™ is developing encapsulated therapies for regenerative medicine and oncologic indications using technology that allows Cytori to use the benefits of its encapsulation platform to develop novel therapeutic strategies and reformulate other drugs to optimize their clinical properties.

  • GlobeNewswire3 months ago

    Cytori Provides Update on US Manufacturing and EU Approval Plans for ATI-0918, Liposomal Doxorubicin

    Cytori Therapeutics, Inc. (CYTX) (“Cytori” or “the Company”) today provided an update on its plans for US manufacturing and EU approval for its ATI-0918 liposomal doxorubicin product. ATI-0918 has been designed and developed to be bioequivalent to the market leading branded reference drug, Caelyx/Doxil (Johnson & Johnson). Liposomal doxorubicin is a commonly used cytotoxic agent for recurrent breast and ovarian cancer, multiple myeloma and Kaposi’s sarcoma.

  • ACCESSWIRE4 months ago

    Blog Exposure - Biohaven Reported Positive Top-line Results For its Two Pivotal Phase-3 Trials of Rimegepant

    Stock Monitor: Cytori Therapeutics Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 28, 2018 / Active-Investors.com has just released a free research report on Biohaven Pharma Holding Co. Ltd. (NYSE: ...

  • Thomson Reuters StreetEvents4 months ago

    Edited Transcript of CYTX earnings conference call or presentation 8-Mar-18 10:30pm GMT

    Q4 2017 Cytori Therapeutics Inc Earnings Call

  • Associated Press4 months ago

    Cytori reports 4Q loss

    The San Diego-based company said it had a loss of 20 cents per share. Losses, adjusted for non-recurring costs, came to 10 cents per share. The developer of cell therapies posted revenue of $1.5 million ...

  • Want To Invest In Cytori Therapeutics Inc (NASDAQ:CYTX)? Here’s How It Performed Lately
    Simply Wall St.4 months ago

    Want To Invest In Cytori Therapeutics Inc (NASDAQ:CYTX)? Here’s How It Performed Lately

    Today I will take a look at Cytori Therapeutics Inc’s (NASDAQ:CYTX) most recent earnings update (30 September 2017) and compare these latest figures against its performance over the past fewRead More...

  • Benzinga4 months ago

    Cytori Therapeutics Q4 Earnings Preview

    On Thursday, Cytori Therapeutics (NASDAQ: CYTX ) will release its latest earnings report. Here is Benzinga's outlook for the company. Earnings and Revenue Wall Street expects EPS loss of 6 cents and sales ...